Skip to main content

BMO Capital Remains a Buy on AbCellera Biologics (ABCL)

Tipranks - Tipranks - Thu Feb 26, 6:44AM CST

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on AbCellera Biologics, with a price target of $7.00. The company’s shares closed yesterday at $3.22.

Claim 50% Off TipRanks Premium

According to TipRanks, Seigerman is a 5-star analyst with an average return of 10.0% and a 55.39% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Disc Medicine, and Novo Nordisk.

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $7.00.

See the top stocks recommended by analysts >>

Based on AbCellera Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $8.96 million and a GAAP net loss of $57.12 million. In comparison, last year the company earned a revenue of $6.51 million and had a GAAP net loss of $51.11 million

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).